BioCentury | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

...end of the month. RoosterBio manufactures human mesenchymal stem cells. Theratechnologies files for NASDAQ listing Theratechnologies Inc....
...assesses cell samples to detect DNA sequences, location and orientation. BioCentury Staff Albuvirtide Frontier Biotechnologies Co. Ltd. KromaTiD Inc. RoosterBio Inc. Theratechnologies Inc. Portola...
BioCentury | Aug 10, 2019
Company News

Aug. 9 Company Quick Takes: Nektar, Novo, Biktarvy, Autolus and more

...in 2H20. The latter two trials are in T cell lymphoma. Theratechnologies regains Egrifta rights Theratechnologies Inc....
BioCentury | Jul 27, 2019
Company News

Vitrakvi set to become EU’s first tissue-agnostic cancer drug

...Next Act" ). Other new therapies backed by CHMP include anti-CD4 mAb Trogarzo ibalizumab-uiyk from Theratechnologies Inc....
...LOXO-101) Acorda Therapeutics Inc. Alexion Pharmaceuticals Inc. Amgen Inc. Bayer AG GW Pharmaceuticals plc Johnson & Johnson Merck & Co. Inc. PTC Therapeutics Inc. Roche Servier Theratechnologies Inc. UCB...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Oct 2, 2018
Company News

Management tracks: Synlogic, Trevena, Editas

...years in the role. Hogan will remain as a consultant until April 2019. HIV company Theratechnologies Inc....
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy Theratechnologies Inc....
BioCentury | Mar 9, 2018
Clinical News

FDA approves mAb for multidrug-resistant HIV

...heavily treatment-experienced patients with HIV-1 whose infections cannot be treated successfully with existing multidrug-resistant therapies. Theratechnologies Inc....
...Roche (SIX:ROG; OTCQX:RHHBY). Genentech Inc., South San Francisco, Calif. TaiMed Biologics Inc. (TPEx:4147), Taipei, Taiwan Theratechnologies Inc....
...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Trogarzo ibalizumab-uiyk Business: Infectious Paul Bonanos ibalizumab (TMB-355, tnx-355, Hu5A8) TaiMed Biologics Inc. Theratechnologies Inc. WuXi...
BioCentury | Mar 7, 2018
Company News

WuXi Biologics, TaiMed rise after FDA approves mAb for HIV

...Inc. (TPEx:4147), which submitted Trogarzo's NDA to FDA, rose NT$21 (10%) to NT$234 on Wednesday. Theratechnologies Inc....
...heavily treatment-experienced patients with HIV-1 whose infections cannot be treated successfully with existing multidrug-resistant therapies. Theratechnologies...
...and has Fast Track, breakthrough therapy and Orphan Drug status to treat HIV. Paul Bonanos ibalizumab TaiMed Biologics Inc. Theratechnologies Inc. WuXi...
BioCentury | Mar 6, 2018
Company News

FDA approves mAb for multidrug-resistant HIV

...heavily treatment-experienced patients with HIV-1 whose infections cannot be treated successfully with existing multidrug-resistant therapies. Theratechnologies Inc....
...distribute the drug from TaiMed Biologics Inc. (TPEx:4147), gained C$2 (28%) to C$9.23 on Tuesday. Theratechnologies...
...approval during market hours in Toronto and after market close in Taipei. Paul Bonanos ibalizumab Genentech Inc. Roche TaiMed Biologics Inc. Theratechnologies Inc. CD4...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) / Pfizer Inc. (NYSE:PFE) Fremanezumab Prevent migraine PDUFA date Mid-2018 Theratechnologies Inc....
Items per page:
1 - 10 of 314
BioCentury | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

...end of the month. RoosterBio manufactures human mesenchymal stem cells. Theratechnologies files for NASDAQ listing Theratechnologies Inc....
...assesses cell samples to detect DNA sequences, location and orientation. BioCentury Staff Albuvirtide Frontier Biotechnologies Co. Ltd. KromaTiD Inc. RoosterBio Inc. Theratechnologies Inc. Portola...
BioCentury | Aug 10, 2019
Company News

Aug. 9 Company Quick Takes: Nektar, Novo, Biktarvy, Autolus and more

...in 2H20. The latter two trials are in T cell lymphoma. Theratechnologies regains Egrifta rights Theratechnologies Inc....
BioCentury | Jul 27, 2019
Company News

Vitrakvi set to become EU’s first tissue-agnostic cancer drug

...Next Act" ). Other new therapies backed by CHMP include anti-CD4 mAb Trogarzo ibalizumab-uiyk from Theratechnologies Inc....
...LOXO-101) Acorda Therapeutics Inc. Alexion Pharmaceuticals Inc. Amgen Inc. Bayer AG GW Pharmaceuticals plc Johnson & Johnson Merck & Co. Inc. PTC Therapeutics Inc. Roche Servier Theratechnologies Inc. UCB...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Oct 2, 2018
Company News

Management tracks: Synlogic, Trevena, Editas

...years in the role. Hogan will remain as a consultant until April 2019. HIV company Theratechnologies Inc....
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy Theratechnologies Inc....
BioCentury | Mar 9, 2018
Clinical News

FDA approves mAb for multidrug-resistant HIV

...heavily treatment-experienced patients with HIV-1 whose infections cannot be treated successfully with existing multidrug-resistant therapies. Theratechnologies Inc....
...Roche (SIX:ROG; OTCQX:RHHBY). Genentech Inc., South San Francisco, Calif. TaiMed Biologics Inc. (TPEx:4147), Taipei, Taiwan Theratechnologies Inc....
...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Trogarzo ibalizumab-uiyk Business: Infectious Paul Bonanos ibalizumab (TMB-355, tnx-355, Hu5A8) TaiMed Biologics Inc. Theratechnologies Inc. WuXi...
BioCentury | Mar 7, 2018
Company News

WuXi Biologics, TaiMed rise after FDA approves mAb for HIV

...Inc. (TPEx:4147), which submitted Trogarzo's NDA to FDA, rose NT$21 (10%) to NT$234 on Wednesday. Theratechnologies Inc....
...heavily treatment-experienced patients with HIV-1 whose infections cannot be treated successfully with existing multidrug-resistant therapies. Theratechnologies...
...and has Fast Track, breakthrough therapy and Orphan Drug status to treat HIV. Paul Bonanos ibalizumab TaiMed Biologics Inc. Theratechnologies Inc. WuXi...
BioCentury | Mar 6, 2018
Company News

FDA approves mAb for multidrug-resistant HIV

...heavily treatment-experienced patients with HIV-1 whose infections cannot be treated successfully with existing multidrug-resistant therapies. Theratechnologies Inc....
...distribute the drug from TaiMed Biologics Inc. (TPEx:4147), gained C$2 (28%) to C$9.23 on Tuesday. Theratechnologies...
...approval during market hours in Toronto and after market close in Taipei. Paul Bonanos ibalizumab Genentech Inc. Roche TaiMed Biologics Inc. Theratechnologies Inc. CD4...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) / Pfizer Inc. (NYSE:PFE) Fremanezumab Prevent migraine PDUFA date Mid-2018 Theratechnologies Inc....
Items per page:
1 - 10 of 314